Audentes Therapeutics to Participate in the Bank of America Merrill Lynch 2019 Health Care Conference

May 8, 2019 |

1 min read

Audentes Therapeutics, Inc. (Nasdaq: BOLD), a leading AAV-based genetic medicines company focused on developing and commercializing innovative products for serious rare neuromuscular diseases, today announced that it will participate in the Bank of America Merrill Lynch Health Care Conference, taking place May 15-17 in Las Vegas, NV.

SAN FRANCISCO, May 8, 2019 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a leading AAV-based genetic medicines company focused on developing and commercializing innovative products for serious rare neuromuscular diseases, today announced that it will participate in the Bank of America Merrill Lynch Health Care Conference, taking place May 15-17 in Las Vegas, NV.

Matthew R. Patterson, Chairman and Chief Executive Officer, will participate in the following events during the conference:

Fireside Chat
Wednesday, May 15, 2019, at 3:40 pm PDT

Panel Discussion: Gene Therapy Landscape
Wednesday, May 15, 2019, at 4:20 pm PDT

To access a live webcast of the fireside chat, please visit the Events & Presentations page within the Investors + Media section of the Audentes website. A replay of the live webcast will be available on the Audentes website for approximately 30 days following the conference.

About Audentes Therapeutics, Inc.
Audentes Therapeutics (Nasdaq: BOLD) is a leading AAV-based genetic medicines company focused on developing and commercializing innovative products for serious rare neuromuscular diseases. We are leveraging our AAV gene therapy technology platform and proprietary manufacturing expertise to develop programs across three modalities: gene replacement, vectorized exon skipping, and vectorized RNA knockdown. Our product candidates are showing promising therapeutic profiles in clinical and preclinical studies across a range of neuromuscular diseases. Audentes is a focused, experienced and passionate team driven by the goal of improving the lives of patients.

For more information regarding Audentes, please visit www.audentestx.com.

Audentes Contacts:

Investor Contact:
Andrew Chang
415.818.1033
achang@audentestx.com

Media Contacts:
Sarah Spencer
415.957.2020
sspencer@audentestx.com

Katie Hogan
415.951.3398
khogan@audentestx.com

Audentes Therapeutics, Inc. (PRNewsfoto/Audentes Therapeutics, Inc.)